Safety and Tolerability of Wharton's Jelly-Derived Mesenchymal Stem Cells for Patients With Duchenne Muscular Dystrophy: A Phase 1 Clinical Study.

In the pulmonary function test, lung capacity (quantified as FVC%) presented an increasing trend at week 12 in the high- and low-dose groups ( Fig. 2 ), and at week 36 in the low-dose group ( Supplementary Fig. 1 in the online-only Data Supplement), but without significance.

also in 63,971 other papers

Serum CK levels showed a decreasing trend from EN001 administration to week 12 ( Fig. 4 ) but without significance.

also in 47,180 other papers